UroGen Pharma (URGN) 2024 Cantor Fitzgerald Global Healthcare Conference summary

Company overview and technology

• Focuses on addressing unmet needs in urologic cancers, particularly highly recurrent, non-curable diseases in elderly patients.

• Developed RTGel, a reverse thermal gel that enables sustained drug delivery to the urothelium, overcoming challenges of drug washout.

• First product, JELMYTO, targets low-grade upper tract urothelial carcinoma and has been commercialized for about four years.

Market opportunity and product differentiation

• JELMYTO addresses a rare disease with about 6,000 patients annually in the US and current market penetration of 12%.

• UGN-102, the next product, targets a much larger market of 80,000 patients, with a potential market size exceeding $5 billion.

• UGN-102 is easier to administer than JELMYTO, requiring less technical expertise and can be delivered in an office setting by a nurse.

Clinical data and regulatory pathway

• ENVISION study showed 80% of patients were disease-free at three months, with durability of response also around 80% at 12 months.

• ATLAS study, though closed early, supported ENVISION results with similar durability and response rates.

• NDA for UGN-102 submitted; expecting priority review decision by mid-October, with potential approval as early as mid-February.

• FDA's main concerns are paradigm shift in treatment and monitoring for disease progression and adverse events.